ReviewFrontiers in oncology2023
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.Blood · 2025Trial
- Article
- Article
- Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells.International journal of molecular sciences · 2026Article
- Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.British journal of haematology · 2026Article
- Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.Blood cancer journal · 2026Article
- Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.Blood · 2026Article
- CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.Hematology. American Society of Hematology. Education Program · 2025Review
- The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?Cancers · 2025Article
- An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.Annals of hematology · 2025Article
- Tregs at Diagnosis as a Potential Biomarker for Predicting High-Risk Functionality in Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy.Blood cancer journal · 2025Article
- Extramedullary Multiple Myeloma: Challenges and Opportunities.Current oncology (Toronto, Ont.) · 2025Review
- Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA.Frontiers in oncology · 2025Article
- Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.Cancer medicine · 2025Article
- Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.European journal of haematology · 2025Observational
- Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria.Mediterranean journal of hematology and infectious diseases · 2025Review
- Efficacy and Safety of Teclistamab Followed by Autologous Stem Cell Transplant in Functional High-risk and Triple-class Refractory Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional prognostic models for newly diagnosed patients with multiple myeloma (MM), including International Staging System criteria and number of high-risk chromosomal abnormalities, are based on disease characteristics at diagnosis. However, the identification of patients at risk of more rapidly progressive MM is inherently a dynamic assessment. In a subset of patients with MM, adverse disease biology only becomes evident after the failure of first-line therapy. We define this entity as functional high-risk MM (FHRMM), encompassing relapse within 18 months of treatment initiation and/or within 12 months of frontline autologous stem cell transplantation. FHRMM is not adequately captured by traditional prognostic models, and there is a need for better understanding of mechanisms or risk factors for early relapse or progression. In this review, we explore potential definitions of FHRMM before delving into its underlying drivers based on genetic, transcriptomic, and immune cell profiling studies. Emerging data suggest that specific features of both myeloma cells and immune cells can enable the FHRMM phenotype. We conclude our review by discussing ongoing and future studies that seek to identify and intervene upon patients with FHRMM preemptively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.